Needham & Company analyst Alan Carr downgraded Neurocrine Bio. (NASDAQ: NBIX) from Buy to Hold.Carr commented, "In our opinion, the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE